Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim clinical data from its ...

Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL ...

Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/ ...

From reference managers to note-taking apps, and presentation tools, the research and writing process is getting a high-tech ...

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient populationEncouraging safety and ...

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...

When Connor Fitzgerald sits down to create a lesson plan for his high school English class, he goes about it a little ...

Good afternoon. Welcome to Fabrinet's Financial Results Conference Call for the First Quarter of Fiscal Year 2026. [Operator Instructions] As a reminder, today's call is being recorded. I would now ...

For much of the past century, visitors watched the sunset from a panoramic point atop Mt. Cheaha now blocked by construction.

For Cole Wehrle, the designer behind Arcs, Root, and John Company, "games are not just their pieces" - they are an ongoing conversation.